Investor Alert

July 30, 2021, 4:53 a.m. EDT

Global Sunitinib Malate Market Size, Share to record considerable growth over 2021-2027

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Jul 30, 2021 (Market Insight Reports) -- Selbyville, Delaware, According to the research report titled 'Global Sunitinib Malate Market Size study, by Type (purity:>99%)(purity:>98%)(purity:>97%), by Application (Pancreatic Neuroendocrine Tumors, Kidney Cancer, Gastrointestinal stromal tumor) and Regional Forecasts 2021-2027', available with Market Study Report LLC, global sunitinib malate market size is projected to grow substantially over 2021-2027.

Rising pervasiveness of pancreatic cancer and technological advancements are the key factors driving global sunitinib malate market growth, cites the study.

Request a Sample Report of Sunitinib Malate Market at: https://www.marketstudyreport.com/request-a-sample/3930293/?utm_source=Marketwatch.com/&utm_medium=SP

As per the American Cancer Society, more than 56,000 Americans were diagnosed with pancreatic cancer in 2017, with over 42,000 expected to die from the disease. Pancreatic cancers are more difficult to diagnose and remove than other tumors due to their relative inaccessibility. Thus, there is a high demand for sunitinib malate capsules to treat such cancers, which further adds to the market development.

For the unaware, sunitinib malate is a small-molecule drug that inhibits several tyrosine kinases in various receptors (RTKs). Its potential antineoplastic action makes it an effective medication in reducing cell proliferation and angiogenesis. Renal cancer, pancreatic neuroendocrine tumors, and gastrointestinal stromal tumors (GST) can all be treated using sunitinib capsules.

Notably, sunitinib was the first cancer medication to be approved for both renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor (GIST) at the same time.

Speaking of negatives, hefty cost of sutent, as well as research & development is likely to impede worldwide sunitinib malate industry expansion over 2021-2027.

Based on type, the market is split into purity: >97%, purity: >98%, and purity: >99%. As per application spectrum, the industry segmentation comprises gastrointestinal stromal tumor, kidney cancer, and pancreatic neuroendocrine tumors.

Top firms operating in global sunitinib malate marketplace are Ferring Pharmaceuticals Inc., Dendreon Corporation, Astellas Pharma Inc., Teva Pharmaceutical Industries Ltd., Synthland Ltd., TargetMol (Target Molecule Corp.), J&K Scientific Ltd., Nanjing First Pharmaceutical Co. Ltd., Top Care Pharmacy, and Pfizer Inc.

Elaborating on regional front, North America, Asia Pacific, Europe, and Latin America are the leading contributors to the overall industry progression. Of these, North America leads the overall market share owing to rising pervasiveness of pancreatic cancer.

On the other hand, Asia Pacific market is projected to accrue high profits by the year 2027, attributable to rising cognizance regarding pancreatic cancer in developing countries like China, India, and others.

For More Details on Sunitinib Malate Market Report at: https://www.marketstudyreport.com/reports/global-sunitinib-malate-market-size-research?utm_source=Marketwatch.com/&utm_medium=SP

About Us:

Market Study Report, LLC. is a hub for market intelligence products and services.

We streamline the purchase of your market research reports and services through a single integrated platform by bringing all the major publishers and their services at one place.

Our customers partner with Market Study Report, LLC. to ease their search and evaluation of market intelligence products and services and in turn focus on their company's core activities.

If you are looking for research reports on global or regional markets, competitive information, emerging markets and trends or just looking to stay on top of the curve then Market Study Report, LLC. is the platform that can help you in achieving any of these objectives.

Contact Us:

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.